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creativecommons.org/licenses/by-nc-nd/Abstract Objective: Rolapitant, a novel neurokinin-1 receptor antagonist (RA), was shown
to protect against delayed chemotherapy-induced nausea and vomiting (CINV) during the first
cycle of moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy
(HEC) in randomized, double-blind trials. This analysis explored the efficacy and safety of ro-
lapitant in preventing CINV over multiple cycles of MEC or HEC.
Patients and methods: Patients in one phase III MEC, one phase II HEC, and two phase III
HEC clinical trials were randomized to receive oral rolapitant (180 mg) or placebo in combi-
nation with a 5-hydroxytryptamine type 3 RA and dexamethasone. Regardless of response in
cycle 1, patients could continue the same antiemetic treatment for up to six cycles. On days 6
8 of each subsequent chemotherapy cycle, patients reported the incidence of emesis and/or
nausea interfering with normal daily life. Post hoc analyses of pooled safety and efficacy data
from the four trials were performed for cycles 2e6.
Results: Significantly more patients receiving rolapitant than control reported no emesis or
interfering nausea (combined measure) in cycles 2 (p Z 0.006), 3 (p < 0.001), 4
(p Z 0.001), and 5 (p Z 0.021). Over cycles 16, time-to-first emesis was significantly longerOncology Centre of Rosebank, 129 Oxford Road, Corner Northwold, Saxonwold, Johannesburg, 2196,
t.co.za (B. Rapoport).
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B. Rapoport et al. / European Journal of Cancer 57 (2016) 23e3024with rolapitant than with control (p < 0.001). The incidence of treatment-related adverse
events during cycles 2e6 was similar in rolapitant (5.5%) and control (6.8%) arms. No cumu-
lative toxicity was observed.
Conclusions: Over multiple cycles of MEC or HEC, rolapitant provided superior CINV pro-
tection and reduced emesis and nausea interfering with daily life compared with control and
remained well tolerated.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chemotherapy-induced nausea and vomiting (CINV) is
a debilitating side-effect of anticancer treatment that
significantly impairs quality of life for patients [1,2]. Use
of a 5-hydroxytryptamine type 3 (5-HT3) receptor
antagonist (RA), particularly when combined with
dexamethasone, has proven highly efficacious for con-
trolling nausea and vomiting that occur in the acute
phase (24 h) following administration of emetogenic
chemotherapy; however, its efficacy in controlling CINV
during the delayed phase (>24e120 h) is limited [3].
Because patients with acute CINV became uncommon
in the clinic following the introduction of 5-HT3 RAs,
health care professionals may not be aware of delayed
CINV. Current antiemetic guidelines recommend the
addition of a neurokinin-1 (NK-1) RA to a 5-HT3 RA
and dexamethasone in patients receiving highly emeto-
genic chemotherapy (HEC) [3e5]. For patients receiving
moderately emetogenic chemotherapy (MEC), the
addition of an NK-1 RA is supported for select patients
with additional CINV risk factors [3,4].
In clinical practice, patients typically receive four to
six cycles of chemotherapy. The severity of CINV can
increase over repeated chemotherapy cycles when CINV
protection is not achieved [6e8], and failure to protect
against delayed CINV can impair protection against
acute CINV in subsequent cycles [8]. Anticipatory
CINV may also develop, which may compromise
adherence to anticancer treatment [9].
The goal of developing new antiemetics should be to
improve CINV protection throughout the entire at-risk
period, with preservation of the benefit over multiple
chemotherapy cycles while maintaining safety and
tolerability. Improved CINV protection over multiple
cycles has been shown with the addition of an NK-1 RA
to standard therapy in studies of aprepitant [10e13] and
netupitant [14]. However, the use of these agents may be
complicated by their interaction with the cytochrome
P450 3A4 (CYP3A4) enzyme, often necessitating dose
adjustment of certain concomitantly administered
medications [15,16].
Rolapitant (VARUBI) is an orally active, long-
acting NK-1 RA that was recently approved by the US
Food and Drug Administration in combination withother antiemetic agents in adults for the prevention of
delayed nausea and vomiting associated with initial and
repeat courses of emetogenic cancer chemotherapy [17].
At the 180-mg dose of rolapitant, the mean NK-1 re-
ceptor occupancy was >90% in the cortex and 73% in
the striatum at 120 h after a single oral dose [18],
consistent with its long half-life (approximately 180 h)
[19]. In addition, rolapitant does not inhibit or induce
CYP3A4; therefore, it may reduce the potential for
CYP3A4-mediated drug-drug interactions and decrease
the need for dose modification of certain drugs metab-
olized by CYP3A4 [20]. An intravenous version of
rolapitant is under investigation.
The efficacy of oral rolapitant (180 mg) in protecting
against CINV was established in four randomized,
placebo-controlled double-blind studies [21e23]. A
greater percentage of patients administered MEC or
HEC demonstrated a complete response (CR: defined as
no emesis and no use of rescue medication) in the
delayed phase (>24e120 h) in cycle 1 with rolapitant
combined with a 5-HT3 RA and dexamethasone
compared with a 5-HT3 RA and dexamethasone alone
[21e23]. The proportion of patients in rolapitant and
control groups who achieved a CR in the delayed phase
(the primary end-point) was 71.3% and 61.6%, respec-
tively, in a phase III MEC study (p < 0.001) and 71.4%
and 60.2%, respectively, in two pooled phase III
cisplatin-based HEC studies (p < 0.001) [21,22]. It
should be noted that 53% of patients in the MEC study
received anthracycline/cyclophosphamide (AC)based
chemotherapy, which is now classified as HEC [3e5];
other patients received a variety of MEC agents, the
most common of which was carboplatin (30% of pa-
tients), and a higher CR rate in the delayed phase with
rolapitant was maintained in this group [21]. In addi-
tion, in a phase II cisplatin-based HEC study, CR in the
delayed phase (a secondary end-point) was achieved by
63.6% and 48.9% of patients in rolapitant and control
groups, respectively (p Z 0.045) [23]. Collectively, these
data support the recently updated National Compre-
hensive Cancer Network guidelines that recommend
rolapitant (category 1) for CINV prevention in patients
receiving HEC and in select patients receiving MEC [3].
Patients who completed cycle 1 in the rolapitant
studies had the option to continue the same randomized
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their response in cycle 1. Here, we report the efficacy and
safety of rolapitant over multiple cycles of MEC or
HEC in a pooled analysis of the four similarly designed
studies: one phase III MEC study (randomized
N Z 1369) [21], one phase II HEC study (randomized
N Z 181) [23], and two phase III HEC studies (ran-
domized N Z 1087) [22].
2. Patients and methods
Four global, randomized, double-blind, placebo-
controlled studies (NCT01500226, NCT00394966,
NCT01499849 and NCT01500213) were conducted in
North America, Central and South America, Europe,
Asia, and Africa in accordance with the Declaration of
Helsinki and the International Conference on Harmo-
nisation and Good Clinical Practice (GCP) guidelines.
The institutional review boards at each study site
approved the protocols. All patients provided written
informed consent.
2.1. Patients
Eligibility requirements for each study included patient
age 18 years, Karnofsky performance score 60, pre-
dicted life expectancy 4 months (3 months in the
phase II study), and adequate bone marrow, kidney, and
liver function. Patients in the MEC study were required
to be naive to MEC or HEC and scheduled to receive a
first course of one or more of the following agents:
intravenous cyclophosphamide (<1500 mg/m2), doxo-
rubicin, epirubicin, carboplatin, idarubicin, ifosfamide,
irinotecan, daunorubicin, and/or intravenous cytarabine
(>1 g/m2). The MEC study was designed before AC-
based chemotherapy was reclassified as HEC; the
study protocol prespecified that at least 50% of patients
enrolled were to receive an AC-based regimen. In the
HEC studies, patients were required to be naive to
cisplatin and scheduled to receive their first course of
cisplatin-based chemotherapy (70 mg/m2 in the phase
II study and 60 mg/m2 in the phase III studies).
Prior to initiating study drug, patients were not
permitted to use any of the following medications: 5-HT3
RAs, phenothiazines, benzamides, domperidone, can-
nabinoids, NK-1 RAs, or benzodiazepines within 48 h;
palonosetron within 7 d; or systemic corticosteroids or
sedative antihistamines (e.g. dimenhydrinate or diphen-
hydramine) within 72 h of day 1, with the exception of
premedication for chemotherapy (e.g. taxanes).
2.2. Treatment
Patients were stratified by sex (and concomitant
emetogenic chemotherapy in the phase II study) and
randomized using an interactive, web-based randomi-
zation system to receive either oral rolapitant 180 mg orplacebo approximately 1e2 h before receiving either
MEC or HEC. All patients received a 5-HT3 RA and
dexamethasone regimen. Patients in the MEC study
were administered oral granisetron 2 mg on days 1e3
and dexamethasone 20 mg on day 1. Patients in the
cisplatin-based HEC studies were administered intrave-
nous granisetron 10 mg/kg (intravenous ondansetron
32 mg in the phase II trial) on day 1 and oral dexa-
methasone 20 mg on day 1 and 8 mg twice daily on days
2e4. Patients administered taxanes received dexameth-
asone according to the package insert.
2.3. Efficacy and safety assessments
During the first 5 days after administration of chemo-
therapy in cycle 1, patients used a daily diary to record
all events of vomiting and use of rescue medication and
to self-assess nausea. The primary end-point was CR in
the delayed phase in the phase III studies and CR in the
overall phase (0120 h) in the phase II study. At the end
of cycle 1, eligible patients were permitted to continue
the same randomized treatment regimen for up to five
additional cycles whether or not they achieved a CR in
cycle 1. Response in cycles 2e6 was assessed for the
exploratory end-points of no emesis or nausea that
interfered with normal daily life (a combined measure),
no emesis, no interfering nausea, and time-to-first
emesis. Patients were asked the following two CINV
assessment questions on days 6e8 of each subsequent
cycle: 1) have you had any episode of vomiting or
retching since your chemotherapy started in this cycle?
and 2) have you had any nausea since your chemo-
therapy started in this cycle that interfered with normal
daily life?
Safety variables, including treatment-emergent
adverse events (TEAEs), physical and neurological ex-
aminations, vital signs, electrocardiograms, and clinical
laboratory values, were assessed in all cycles.
2.4. Statistical analysis
Post hoc analyses of pooled safety and efficacy data
from the four studies were performed for cycles 2e6
(only data from patients receiving the 180-mg rolapitant
dose or control were included from the dose-finding
phase II HEC study). The subsequent cycle efficacy
population consisted of all patients who received at least
one dose of study drug in a given cycle and were enrolled
at a GCP-compliant site. Between-group comparisons
were conducted using the CochraneManteleHaenszel
c2 test adjusted for sex and study. Time-to-first emesis
was summarized using KaplaneMeier methodology,
and the between-group treatment comparison was con-
ducted using a log-rank test in the population of patients
who received study drug at a GCP-compliant site.
p-values <0.05 were considered statistically significant
and were not adjusted for multiplicity.
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received at least one dose of study drug in a given
cycle.
3. Results
3.1. Patients
Baseline characteristics were balanced between pa-
tients in the rolapitant and control groups in the
overall pooled analysis (Table 1). The majority of
patients in the MEC study were female (80%), and
breast cancer was the most commonly diagnosed
malignancy (67%) [21]. AC-based chemotherapy (now
classified as HEC [3e5]) was received by 53% of pa-
tients, and carboplatin-based chemotherapy was
received by 30% of patients; other patients received a
variety of MEC regimens (Supplemental Table 1) [21].
In the pooled phase III cisplatin-based HEC studies,
the majority of patients were male (63%) and lung
cancer was the most commonly diagnosed malignancy
(44%) [22].
Patient discontinuations occurred with similar fre-
quencies in both treatment arms for cycle 1 and the
combined cycles 2e6 (Fig. 1). The most common reason
for patient discontinuation was completion of the
required number of chemotherapy cycles (observed in
36.0% of patients overall). This most often occurred
after four cycles, a typical treatment course for many
chemotherapy regimens, with 34.0% and 37.2% of pa-
tients discontinuing after cycle 4 in the rolapitant and
control arms, respectively (Supplemental Table 2).Table 1
Baseline demographicsa.
Characteristics Rolapitant, 180 mg (n
Age, y, median (range) 58 (20e86)
Sex, n (%)
Female 620 (61.6)
Male 387 (38.4)
Race, n (%)
White 806 (80.0)
Asian 95 (9.4)
Black or African American 23 (2.3)
American Indian/Alaska Native 13 (1.3)
Native Hawaiian/other Pacific islander 1 (0.1)
Multiracial/other/unknown 69 (6.9)
Alcohol consumptionb
0e5 Drinks/week, n/N (%) 890/943 (94.4)
>5 Drinks/week, n/N (%) 53/943 (5.6)
Region, n (%)
North America 224 (22.2)
Central/South America 109 (10.8)
Europe 554 (55.0)
Asia/South Africa 120 (11.9)
a Demographics shown are for patients who received the 180-mg rolapi
compliant site.
b Data for alcohol consumption were not collected in the phase II study3.2. Efficacy
Over multiple cycles, a greater proportion of patients in
the rolapitant group than the control group reported no
emesis or interfering nausea (combined measure); the
improvement reached statistical significance in cycles 2
(p Z 0.006), 3 (p < 0.001), 4 (p Z 0.001), and 5
(p Z 0.021, Fig. 2A). A significantly higher proportion
of patients reported no emesis events in the rolapitant
group than the control group in cycles 2e6 (p < 0.001
for each subsequent cycle, Fig. 2B). A significantly
greater percentage of patients reported no interfering
nausea with rolapitant versus control in cycles 2
(p Z 0.010), 3 (p < 0.001), 4 (p Z 0.012), and 5
(p Z 0.029, Fig. 2C), but not in cycle 6 (p Z 0.682).
There was a general trend of decreased CINV over
repeated cycles in the control group. However, the
improvement in no emesis and no interfering nausea
(combined and individual measures) with rolapitant
relative to control remained generally consistent over
multiple cycles.
KaplaneMeier curves showing time-to-first emesis
separated in cycle 1 and favored rolapitant over control
with sustained separation that remained consistent over
cycles 2e6 (p < 0.001, Fig. 3).
3.3. Safety
The safety dataset comprised 1012 patients who received
rolapitant and 999 patients who received control in cy-
cles 2e6. Rolapitant was well tolerated over multiple
cycles of MEC or HEC, with an incidence of treatment-Z 1007) Control (n Z 991) Total (n Z 1998)
57 (18e90) 57 (18e90)
625 (63.1) 1245 (62.3)
366 (36.9) 753 (37.7)
777 (78.4) 1583 (79.2)
97 (9.8) 192 (9.6)
29 (2.9) 52 (2.6)
13 (1.3) 26 (1.3)
2 (0.2) 3 (0.2)
73 (7.4) 142 (7.1)
849/922 (92.1) 1739/1865 (93.2)
73/922 (7.9) 126/1865 (6.8)
226 (22.8) 450 (22.5)
113 (11.4) 222 (11.1)
530 (53.5) 1084 (54.3)
122 (12.3) 242 (12.1)
tant dose or control during cycles 2e6 at a Good Clinical Practice
and are based on patients who self-reported alcohol consumption.
Randomized (N=2637)
   MEC (n=1369)
   Phase II HEC (n=181)
   HEC1 (n=532)
   HEC2 (n=555)
Completed all 6 cycles (n=298)  
Received control in cycle 1 (n=1301) 
Received control in cycles 2–6 (n=999) 
  Discontinued (n=282)
Consent withdrawn (n=77)
Chemotherapy completed or changed (n=50)
Adverse event (n=38)
Protocol noncompliance (n=34)
Death (n=11)
Disease progression (n=2)
Other (n=70)*
Completed all 6 cycles (n=302) 
Received rolapitant 180 mg in cycles 2–6 (n=1012) 
  Discontinued (n=710)
Chemotherapy completed or changed (n=359)
Consent withdrawn (n=103)
Adverse event (n=64)
Disease progression (n=50)
Protocol noncompliance (n=44)
Death (n=13)
Other (n=77)*
Received rolapitant 180 mg in cycle 1 (n=1294) 
  Discontinued (n=701)
Chemotherapy completed or changed (n=365)   
Consent withdrawn (n=99)
Adverse event (n=66)
Disease progression (n=48)
Protocol noncompliance (n=34)
Death (n=7)
Other (n=82)*
  Discontinued (n=302)
Consent withdrawn (n=97)
Adverse event (n=46)
Chemotherapy completed or changed (n=38)
Protocol noncompliance (n=32)
Death (n=7)
Disease progression (n=4)
Other (n=78)*
Entered multiple cycle 
extension (n=2015)†
Fig. 1. Pooled studies CONSORT flow diagram: *, primary reasons for patient discontinuation in the “other” category include lost to
follow-up, lack of efficacy, investigator judgment, and sponsor decision/study closure and y, two patients in the rolapitant group and two
patients in the control group discontinued before receiving study drug in cycles 2e6. MEC, moderately emetogenic chemotherapy; HEC,
highly emetogenic chemotherapy.
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of the most common treatment-related TEAEs, which
included fatigue, constipation, and headache, was low
(<2%, Table 2). In addition, the incidence of treatment-
related TEAEs over multiple cycles remained similar to
that observed in cycle 1. The incidence of treatment-
related TEAEs did not increase with each subsequent
cycle, and no cumulative toxicity was observed
(Supplemental Table 3). For cycles 2e6, the total
number of patients discontinuing due to an adverse
event, disease progression, or death was low (6.5%,
4.9%, and 1.0% of patients, respectively, Fig. 1).
4. Discussion
Rolapitant combined with a 5-HT3 RA and dexameth-
asone provided superior protection against CINV in
patients receiving multiple cycles of MEC or HEC
compared with a 5-HT3 RA and dexamethasone alone.
In a pooled analysis of four similarly designed phase II
and III studies, the proportion of patients reporting noemesis and no interfering nausea was significantly higher
with rolapitant group than with control over multiple
cycles.
The rolapitant trials included a diverse population of
patients with cancer [21e23], a majority of whom were
at high risk for CINV [1], as 60% of the population in
the pooled analysis was female and over 90% reported
little or no alcohol consumption. In this pooled analysis,
the treatment arms were well balanced for these risk
factors.
In multiple-cycle studies, the incidence of CINV has
generally been found to increase over cycles of chemo-
therapy [7,8]. In contrast, we observed a trend of
decreased CINV over multiple cycles in the control group;
healthier patients may have been more likely to remain in
the study for reasons such as a greater ability to comply
with clinic visit follow-ups as well as a lower rate of disease
progression or death, whereas those with poor CINV
control may have been more likely to discontinue after
cycle 1. Despite this trend, the improvement in patient-
reported outcomes of no emesis and no interfering
A. No emesis or interfering nausea 
Rolapitant 180 mg Control
B. No emesis
C. No interfering nausea
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Fig. 2. Rates of no emesis and/or no interfering nausea in cycles 2e6. Rates of (A) no emesis or interfering nausea (combined measure), (B)
no emesis, and (C) no interfering nausea based on patient response to two yes/no questions about emesis events and nausea interfering
with normal daily life.
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generally consistent over multiple cycles. Furthermore,
KaplaneMeier curves showing time-to-first emesis
demonstrated a consistent improvement favoring rolapi-
tant over control that was sustained over six cycles.There are challenges inherent in collecting data over
multiple cycles of chemotherapy [6]. In an effort to
facilitate data collection, the rolapitant trials used a
simple measure of response in cycles 26. Patients
answered two yes/no questions about whether nausea or
11290
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Fig. 3. Time-to-first emesis over cycles 16. Estimates for the proportions of patients without a first event of emesis in the rolapitant and
control arms over cycles 16.
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instead of using the 5-d daily diary employed in cycle 1
[21,22]. As is typical with multiple-cycle trials [6], the
number of enrolled patients decreased over the course of
six cycles. The frequency of discontinuations in each
cycle was similar in rolapitant and control arms.
Completion of the required number of chemotherapy
cycles was the most common reason for discontinuation
in both arms and occurred most often after four cycles,
which is a typical course for many chemotherapy regi-
mens. The MEC trial included approximately 50% pa-
tients receiving AC-based chemotherapy for breast
cancer [21], which is administered over four cycles [24];
completion of chemotherapy in these patients was a
major reason for the discontinuations in the pooled
analysis. The number of patients who discontinued due
to an adverse event, disease progression, or death was
low in both arms.
In summary, oral rolapitant effectively protected
against CINV, with sustained benefit over multipleTable 2
Treatment-related TEAEs in cycle 1 and cycles 26.
Category Cycle
Rola
180 m
(n Z
Patients with one or more treatment-related TEAE, n (%)a 90 (7
Treatment-related TEAEs (1% of patients in cycle 1 or cycles 2e6), n (%
Fatigue 25 (1
Constipation 20 (1
Headache 19 (1
TEAE Z treatment-emergent adverse event.
a Any adverse event considered possibly, probably, or definitely related tcycles of MEC or HEC. Rolapitant was also well-
tolerated, with no increase in the frequency of
treatment-related TEAEs and no cumulative toxicity
with treatment over multiple cycles. These results sup-
port the benefit of adding rolapitant to the supportive
care of a diverse population of patients with cancer
receiving multiple cycles of MEC or HEC.
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